---
title: "Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302883335.md"
description: "Tempus AI has expanded its partnership with Bristol Myers Squibb (BMS) through a multiyear oncology data licensing agreement extending to 2031. This deal makes BMS one of Tempus's largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development. Additionally, BMS will access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure."
datetime: "2026-10-23T13:02:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302883335.md)
  - [en](https://longbridge.com/en/news/302883335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302883335.md)
generator: "portal-rs"
---

# Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031

-   Tempus AI expanded its collaboration with Bristol Myers Squibb under a multiyear oncology data licensing agreement running through 2031. \* The agreement makes Bristol Myers Squibb one of its largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development. \* Bristol Myers Squibb will also access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023516440) on October 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [TEMC.US](https://longbridge.com/en/quote/TEMC.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development](https://longbridge.com/en/news/302882838.md)
- [Tempus AI Study Shows Pre-Screening Panel Exceeds 80% Sensitivity Across 12 Lung Cancer Biomarkers](https://longbridge.com/en/news/302290117.md)
- [Tempus AI Diagnostics CEO Thomas Edward Schoenherr disposes of $873,885 in common shares](https://longbridge.com/en/news/300480097.md)
- [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md)
- [Tempus AI director Nadja West sells 3,000 shares worth $207,000](https://longbridge.com/en/news/297693362.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**